对于患有炎症性肠道疾病的患者中Clostridioides difficile感染的Fidaxomicin:一个多中心的回顾性队列研究
Daniele Noviello1, María Chaparro2, Chiara Viganò3,4
1Department of Pathophysiology and Transplantation, University of Milan, Milano, Italy.
Journal of Crohn's & colitis
|April 1, 2025
概括
在炎症性肠道疾病 (IBD) 患者中,菲达克索米辛有效治疗了困难结肠杆菌感染 (CDI),显示出10%的复发率. 这种药物在经历首次CDI发作的患者中是安全和更有效的.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠道疾病 (IBD) 患有 Clostridioides difficile 感染 (CDI) 的患者面临更高的不良结果风险.
- 有限的数据存在fidaxomicin的有效性在IBD患者与CDI.
- 这项研究评估了fidaxomicin在一个大型国际IBD患者队列中的有效性和安全性.
研究的目的:
- 评估fidaxomicin治疗CDI的有效性和安全性,在患有性结肠炎 (UC) 或克罗恩病 (CD) 的成年患者中.
- 评估菲达克索米辛治疗对IBD结局的影响,包括复发,治疗升级,切除术和死亡率.
主要方法:
- 对成年UC和CD患者进行了回顾性分析,这些患者因有记录的CDI而接受了fidaxomicin治疗.
- 主要结局:CDI在8周内复发.
- 二次结果:持续反应,IBD治疗升级,切除肠道,以及不同时间点的死亡率.
主要成果:
- 总共有96名患者 (57名UC,39名CD) 被纳入,其中大多数患者接受了先进的IBD治疗.
- 在8周后,CDI复发率为10%,在12周后,持续反应率为82%.
- 菲达克索米辛耐受性良好,仅报告了轻微的不良事件. 首次CDI发作患者的复发率较低,持续反应率更高.
结论:
- 菲达克索米辛在IBD患者中治疗CDI的有效性和安全性得到证明.
- 这种药物在CDI-naive患者中显示出更大的疗效.
- 菲达克索米辛治疗可能会对患有CDI的IBD患者的短期结果产生积极影响.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
109
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
109
Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
91
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
91
Drugs for Treatment of Ulcerative Colitis in IBD
110
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
110
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
259
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
259


